The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between homologous recombination deficiency (HRD) gene mutations and the efficacy of venadaparib in combination with irinotecan as third- or fourth-line treatment in patients with metastatic gastric cancer (mGC).
 
Min-Hee Ryu
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
 
Hyung-Don Kim
Honoraria - AstraZeneca/MedImmune; Boostimmune; Boryung Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Mustbio
Research Funding - Roche/Genentech/Foundation Medicine
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; JW Pharmaceutical; Merck KGaA; Sanofi/Aventis
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Metafines; MSD
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Elevar Therapeutics (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Sun Young Rha
No Relationships to Disclose
 
Seung Tae Kim
No Relationships to Disclose
 
Won Sik Lee
Employment - Idience
Leadership - Idience
 
Min Ju Hong
Employment - Idience
Stock and Other Ownership Interests - Idience
Travel, Accommodations, Expenses - Idience
 
Myongjae Lee
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
Eun-Jihn Roh
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
Kyoung Soo HA
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience